New hope to stop Leukemia's silent return after transplant
NCT ID NCT05940961
First seen Nov 21, 2025 · Last updated Apr 15, 2026 · Updated 19 times
Summary
This study is testing a drug called Inotuzumab Ozogamicin for people with acute lymphoblastic leukemia (ALL) who have had a stem cell transplant but still have tiny, hard-to-detect amounts of cancer cells left. The goal is to see if this drug can safely eliminate these remaining cells to help prevent the cancer from coming back. The trial will enroll about 42 participants to measure how well the drug works and monitor for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC STEM CELL TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.